RBR-2fvjjm招募中未知
Multicenter, prospective, randomized, double-blind clinical trial for the use of Hyperbaric Oxygen Therapy in patients hospitalized with Covid-19
niversidade Federal de Minas Gerais0 个研究点开始时间: 2020年8月11日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Intervention
入排标准
- 年龄范围
- 18Y 至 —（—）
入选标准
- •Both sexes; age above 18 years; presenting with one or more of the following symptoms of acute respiratory infection, such as anosmia and / or dysgeusia, cough, fever above 37.8ºC, dyspnoea, sore throat, coryza; confirmed diagnosis of the disease (SARS-Cov-2) in the last 5 days by one of the current tests (with approval from a state or national regulatory agency); pending laboratory test result (SARS-Cov-2), but patient with a high clinical suspicion for COVID-19 indicated by the mandatory observation of all the following items, cough lasting less than or equal to 10 days, pulmonary infiltrates in the chest image (simple chest X-ray or computed tomography), hypoxemia defined as SaO2 less than or equal to 94%, no alternative explanation for symptoms of acute respiratory infection, recent contact with persons with suspected COVID-19 or recent return from travel from a place with a high number of cases, computed tomography scan of the chest with suggestive changes, performed no more than 24 hours before admission.
排除标准
- •Present an usual contraindication to hyperbaric therapy, including untreated pneumothorax, spherocytosis, recent middle ear surgery, sinusitis, doxorubicin use, bleomycin, disulfiram, cisplatin, mafenide, as well as topical use of iodine and petrolatum.
研究者
相似试验
进行中（未招募）
1 期
Clinical study comparing the action and the safety of two approved drugs for nasal application,containing the same active substance - mupirocin.EUCTR2018-002913-37-BGAntibiotic-Razgrad AD260
招募中
不适用
Multicentre, prospective, randomised, double-blind, placebo-controlled study to evaluate the mechanism of a novel medical device for long-lasting weight loss in overweight and obesity.E66.9Obesity, unspecifiedDRKS00008922Praxis Dr. med. von Seck15
进行中（未招募）
1 期
Clinical trial to assess the efficacy and safety of a vaccine for grasses and olive tree allergyAetiological treatment of moderate-severe intermitent or persistent allergic rhinitis/rhinoconjunctivitis with or without controlled mild-moderate intermittent or persistent allergic asthmaMedDRA version: 20.0Level: LLTClassification code: 10036019Term: Pollen allergy Class: 10021428MedDRA version: 26.0Level: LLTClassification code: 10034382Term: Perennial allergic rhinitis Class: 10038738MedDRA version: 27.0Level: LLTClassification code: 10070526Term: Grass allergy Class: 10021428MedDRA version: 20.0Level: LLTClassification code: 10001728Term: Allergic rhinoconjunctivitis Class: 10015919MedDRA version: 21.1Level: LLTClassification code: 10001705Term: Allergic asthma Class: 10038738CTIS2024-514525-34-00Inmunotek S.L.180
进行中（未招募）
1 期
Clinical trial to asses the efficacy and safety of a vaccine for grasses and cupressaceae allergyAetiological treatment of moderate-severe intermitent or persistent allergic rhinitis/rhinoconjunctivitis with or without controlled mild-moderate intermittent or persistent allergic asthmaMedDRA version: 27.0Level: LLTClassification code: 10070526Term: Grass allergy Class: 10021428MedDRA version: 26.0Level: LLTClassification code: 10034382Term: Perennial allergic rhinitis Class: 10038738MedDRA version: 20.0Level: LLTClassification code: 10001728Term: Allergic rhinoconjunctivitis Class: 10015919MedDRA version: 21.1Level: LLTClassification code: 10001705Term: Allergic asthma Class: 10038738MedDRA version: 20.0Level: LLTClassification code: 10036019Term: Pollen allergy Class: 10021428CTIS2024-514524-16-00Inmunotek S.L.180
进行中（未招募）
1 期
Clinical trial to evaluate the efficacy of a 0.005% estriol vaginal gel in the prevention of recurrent urinary tract infections in postmenopausal women with vaginal atrophy.Recurrent Urinary Tract Infection (UTI) in postmenopausal women with vaginal atrophy.MedDRA version: 20.0Level: LLTClassification code 10038140Term: Recurrent urinary tract infectionSystem Organ Class: 100000004862EUCTR2018-001481-42-ESITF RESEARCH PHARMA S.L.U.120